Ele voltou! Ghostface, um dos maiores vilões do cinema de horror, retorna para estrelar "Pânico 7" e, dessa vez, acompanhado de velhos conhecidos. O novo filme da franquia estreou na última ...
Criada no palco, sempre foi movida pela arte. Defensora ferrenha de Crepúsculo e Ricardo Darín, fala pelos cotovelos sobre as histórias que vemos nas telas e nos bastidores. Neve Campbell, Courtney ...
Falta pouco para o Oscar 2026! A votação para eleger quem levará a estatueta dourada para casa começou na quinta-feira (26) e vai definir os vencedores em 24 categorias da estatueta dourada. Fernanda ...
Novo's drug, CagriSema, didn't achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide. The stock plummeted on Monday, hitting its ...
CagriSema shows 23% weight loss versus 25.5% for Zepbound Novo's shares drop 15% Lilly's shares rise 4% in US pre-market trading Outcome is 'worst-case scenario' for Novo, investor says Few analysts ...
PARIS — Unilever Ventures has taken a minority stake in Novos, a science-first longevity biotech company. Chris Mirabile founded Novos in 2019 and serves as the New York-based company’s chief ...
Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly’s obesity blockbuster Zepbound in a phase 3 weight loss study, further denting the Danish pharma’s attempts to reclaim its obesity crown.
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Novo Nordisk’s next-generation weight loss drug CagriSema, one ...
Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...
Novo Nordisk (NVO) shares fell over 15% on Monday after the company’s next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s (LLY) competing treatment in a phase 3 trial, ...
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead.
LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly (LLY.N), opens new tab streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk (NOVOb.CO), opens new tab needed ...
Novo Nordisk’s board of directors is still going through changes. On top of last fall’s significant shake-up, the company is now nominating two fresh faces to the board, each of whom would bring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results